Increased risk of chronic fatigue syndrome following psoriasis: a nationwide population-based cohort study. Tsai et al 2019

J Transl Med. 2019 May 14;17(1):154. doi: 10.1186/s12967-019-1888-1.
Increased risk of chronic fatigue syndrome following psoriasis: a nationwide population-based cohort study.
Tsai SY1,2,3,4, Chen HJ5,6, Chen C7,8, Lio CF7, Kuo CF9, Leong KH7, Wang YT7, Yang TY10,11, You CH12,13, Wang WS14.
Author information

The onset of chronic fatigue syndrome (CFS) has been shown to be associated with several immunological conditions such as infections or atopy. The aim of this study was to clarify the risk of chronic fatigue syndrome following the diagnosis of psoriasis, an immune-related dermatological disease, by analyzing the National Health Insurance Research Database of Taiwan.
2616 patients aged 20 years or older with newly diagnosed psoriasis during 2004-2008 and 10,464 participants without psoriasis were identified. Both groups were followed up until the diagnoses of CFS were made at the end of 2011.
The relationship between psoriasis and the subsequent risk of CFS was estimated through Cox proportional hazards regression analysis, with the incidence density rates being 2.27 and 3.58 per 1000 person-years among the non-psoriasis and psoriasis populations, respectively (adjusted hazard ratio [HR] = 1.48, with 95% confidence interval [CI] 1.07-2.06). In the stratified analysis, the psoriasis group were consistently associated with a higher risk of CFS in male sex (HR = 2.05, 95% CI 1.31-3.20) and age group of ≥ 60 years old (HR = 2.32, 95% CI 1.33-4.06). In addition, we discovered that the significantly increased risk of CFS among psoriasis patients is attenuated after they receive phototherapy and/or immunomodulatory drugs.
The data from this population-based retrospective cohort study revealed that psoriasis is associated with an elevated risk of subsequent CFS, which is differentiated by sex and age.
Chronic fatigue syndrome; Immune system diseases; National health programs; Psoriasis
PMID: 31088562 DOI: 10.1186/s12967-019-1888-1


Senior Member
If they discover a test for susceptibility for ME, at least there's a possibility of treatments to avoid developing it after an immune activating event. That doesn't help those who have already developed it, but it would still be something worth researching...but not by diverting funds from developing a treatment for ME, please. :)